The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis - Clinical Outcomes (PL02.003)

The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing Remitting Multiple Sclerosis - MRI Outcomes (S11.002)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.s11.002 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. S11.002-S11.002 ◽

Cited By ~ 1

Author(s):

J. Wolinsky ◽

P. Narayana ◽

F. Nelson ◽

S. Datta ◽

S. Cofield ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Randomized Study ◽

Double Blind ◽

Combined Use ◽

Relapsing Remitting ◽

Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.67.4.451 ◽

1999 ◽

Vol 67 (4) ◽

pp. 451-456 ◽

Cited By ~ 18

Author(s):

C. Liu ◽

L. D Blumhardt

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

10.1002/14651858.cd009333 ◽

2011 ◽

Author(s):

Loredana La Mantia ◽

Alberto Vaona ◽

Marco Rovaris ◽

Francesco Berardo ◽

Serena Frau ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Glatiramer Acetate and Interferon Beta (PD5.008)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.pd5.008 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. PD5.008-PD5.008

Author(s):

G. Rojas ◽

C. Vrech ◽

F. Leguizamon ◽

S. Lindembaum ◽

A. Carra

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Clinical Predictors ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Free Status

A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn31557558 ◽

2013 ◽

Author(s):

Mike Boggild

Keyword(s):

Multiple Sclerosis ◽

Randomised Controlled Trial ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Controlled Trial ◽

Sequential Treatment ◽

Relapsing Remitting ◽

Randomised Controlled ◽

A Multi-center, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Methylprednisolone in Combination with Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn68218781 ◽

2013 ◽

Author(s):

Mads Ravnborg

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Double Blind ◽

Parallel Group ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Parallel Group Trial ◽

Group Trial

PNP15: COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)64043-0 ◽

2003 ◽

Vol 6 (3) ◽

pp. 277

Author(s):

C Rubio-Terrés ◽

F Medina ◽

I Aristegui ◽

G Izquierdo

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

Neurology ◽

10.1212/01.wnl.0000243810.20687.51 ◽

2006 ◽

Vol 67 (7) ◽

pp. 1313-1314

Author(s):

D. S. Goodin ◽

N. Koch-Henriksen ◽

P. S. Sorensen

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Randomized Study ◽

Relapsing Remitting ◽

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Journal of Neurology ◽

10.1007/s00415-017-8642-5 ◽

2017 ◽

Vol 264 (12) ◽

pp. 2436-2449 ◽

Cited By ~ 22

Author(s):

Giancarlo Comi ◽

◽

Francesco Patti ◽

Maria Assunta Rocca ◽

Flavia Caterina Mattioli ◽

...

Keyword(s):

Multiple Sclerosis ◽

Multicentre Study ◽

Clinical Outcomes ◽

Interferon Beta ◽

Open Label ◽

Relapsing Remitting ◽